NorthWest Biotherapeutics Inc (NWBO)

[iclight]

1)“What we are currently doing right now is expanding our manufacturing capacity,” Cognate chief operating officer Mike Stella said. “So we can grow with the companies that we currently have as well as bring on additional clients.”

Courtesy of NWBO shareholders

2)"Besides this, the Cell Engineering / GLP Unit attracted numerous new projects with various partners from the biotechnology and pharmaceuticals industry."

Which you left out. You act as if Fraunhofer is only working with NWBO. For all you know, it could be 1 of 100 companies that need a clean room.

3)Detailed negotiations are now underway

Aren't negotiations still underway for HE pricing? And EAMS, and the clinical hold. And everything else NWBO has ever done? They need to get some clean room going because they still aren't developing the vaccine in England and the few English patients who have received it have gotten it from Fraunhofer (assuming you read the whole Fraunhofer report you linked in 2))